Jelle Kuypers Appointed Chief Financial Officer of MedMira

HALIFAX, Dec. 9, 2013 /CNW/ - MedMira, Inc. (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, today announced the appointment of Jelle Kuypers as Chief Financial Officer.

"I'm excited to join the team at MedMira. In addition to leading the Company's financial functions, I look forward to working with the executive and Board to execute on the Company's strategic plan and grow our global presence in order to increase shareholder value," said Jelle Kuypers, Chief Financial Officer, MedMira Inc..

Kuypers brings more than 15 years of leadership experience in finance and treasury, strategic and operational planning, as well as business development. He has in-depth experience in creating and developing high-performance finance teams working in global markets including Europe, North America and the Middle East.

"On behalf of the Board of Directors, I welcome Jelle to the team and look forward to MedMira benefiting from the wealth of financial expertise, corporate strategy building, and international experience that he brings," said Hermes Chan, CEO, MedMira Inc. "Jelle's focus will be on developing a strong financial and organisational platform across our business as we push forward with our strategic initiatives and product launches in the US and international markets to drive positive growth in 2014.

Chan added, "Using his extensive range of financial and business experience, Jelle will lead the development and implementation of key financial and business information systems aimed at streamlining processes and increasing efficiency across the organization."

Prior to joining MedMira, Kuypers served in senior finance and treasury roles in Canada, Switzerland and the Middle East with Rio Tinto Alcan, Sohar Aluminum and Alcan Holdings Switzerland.  He also worked for a number of years as a management consultant with Mercer Management Consulting and KPMG Treasury & Risk Management where he focused on the areas of financial management, supply chain management, controlling, and organizational redesign.  He holds a master's degree in Finance and Economics from the University of St. Gallen (HSG), graduating as lic. oec. HSG. He also earned a CEMS Master's in International Management (CEMS MIM) degree in International Business and Strategies and International Controlling from the Rotterdam School of Management, Erasmus University.

About MedMira

MedMira is the leading developer and manufacturer of flow-through rapid diagnostics and technologies. MedMira is the only Canadian company to be awarded US Army contracts for the development of rapid tests for HIV and Hepatitis viruses.  The Company's testing solutions provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The Company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira is located in Halifax, Nova Scotia, Canada. www.medmira.com.

This news release contains forward-looking statements, including statements relating to growth in the Company's business, earnings and profitability, and trends in demand for the Company's products, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible future growth and new business opportunities.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE MEDMIRA INC.